{"filings":[{"id":3367196,"accession_number":"0001185185-26-004679","cik":1903784,"company_name":"Vogenx, Inc.","ticker":"VOGX","form_type":"8-K","filed_at":"2026-10-09T17:30:37+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vogenx taps board member Richard Gorman as Chief Commercial Officer, effective Oct 12","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Gorman, an independent Vogenx director since 2022, becomes Chief Commercial Officer effective October 12, 2026, a newly created role.","Gorman resigned from the Board and its Audit, Compensation and Nominating/Corporate Governance committees effective Oct 12; no disagreement with the company cited.","He will lead commercial operations and corporate strategy, including market development for post-bariatric hypoglycemia and gastroparesis, plus business development and licensing.","Vogenx will search for a new independent director to fill the board seat; CEO James Green credited Gorman with shaping strategy through the August 2026 IPO.","Company says the hire supports advancing mizagliflozin into later-stage development; Gorman has 30 years of biopharma commercial experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3017677,"accession_number":"0001185185-26-004202","cik":1903784,"company_name":"Vogenx, Inc.","ticker":"VOGX","form_type":"8-K","filed_at":"2026-09-22T20:01:01+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vogenx appoints Ken Toombs to board as independent director and Audit Committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken Toombs, former CEO of PA Consulting, appointed independent Class II director effective Sept 21, 2026.","Toombs will chair Audit Committee; also joins Compensation and Nominating/Governance committees.","Peter Pieraccini named Chair of Compensation Committee, effective Sept 21, 2026.","Appointment follows Vogenx's August 2026 IPO; Toombs brings three decades in life sciences and professional services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2354956,"accession_number":"0001185185-26-003628","cik":1903784,"company_name":"Vogenx, Inc.","ticker":"VOGX","form_type":"8-K","filed_at":"2026-08-19T20:05:28+00:00","items":["8.01"],"status":"ready","headline":"Vogenx closes fully exercised IPO over-allotment, raising $12.2M additional gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 19, 2026, closed on 937,500 additional shares at $13.00 per share under the over-allotment option.","Additional gross proceeds of approximately $12.19M before underwriting discounts, commissions, and offering expenses.","Total offering now 7,187,500 shares with aggregate gross proceeds of approximately $93.44M.","Underwriter JonesTrading exercised the 45-day over-allotment option; initial IPO closed Aug 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2245437,"accession_number":"0001185185-26-003505","cik":1903784,"company_name":"Vogenx, Inc.","ticker":"VOGX","form_type":"8-K","filed_at":"2026-08-13T20:41:52+00:00","items":["5.03","9.01"],"status":"ready","headline":"Vogenx adopts amended charter authorizing 500M common shares, 10M preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second amended and restated certificate of incorporation filed with Delaware, effective immediately prior to IPO.","Charter authorizes 500,000,000 shares of common stock, $0.0001 par value per share.","Charter eliminates prior preferred stock series and authorizes 10,000,000 shares of undesignated preferred stock.","Amended and restated bylaws establish advance notice procedures for stockholder proposals and director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}